Filing Details
- Accession Number:
- 0001209191-19-056090
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-11-12 17:10:00
- Reporting Period:
- 2019-11-08
- Accepted Time:
- 2019-11-12 17:10:00
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1396814 | Pacira Biosciences Inc. | PCRX | Pharmaceutical Preparations (2834) | 510619477 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1709330 | Richard Scranton | C/O Pacira Biosciences, Inc. 5 Sylvan Way, Suite 300 Parsippany NJ 07054 | Chief Scientific Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2019-11-08 | 14,698 | $10.81 | 30,759 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2019-11-08 | 4,750 | $25.37 | 35,509 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2019-11-08 | 19,448 | $45.00 | 16,061 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2019-11-08 | 14,698 | $0.00 | 14,698 | $10.81 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2019-11-08 | 4,750 | $0.00 | 4,750 | $25.37 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2022-06-05 | No | 4 | M | Direct | |
| 20,250 | 2023-03-05 | No | 4 | M | Direct |
Footnotes
- The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
- The stock options are fully vested.
Billionaire Hedge Funds
